Compare · DXCM vs STVN
DXCM vs STVN
Side-by-side comparison of DexCom Inc. (DXCM) and Stevanato Group S.p.A. (STVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and STVN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $27.61B, about 4.6x STVN ($5.96B).
- Over the past year, DXCM is down 20.1% and STVN is down 23.4% - DXCM leads by 3.3 points.
- DXCM has been more active in the news (6 items in the past 4 weeks vs 1 for STVN).
- DXCM has more recent analyst coverage (25 ratings vs 22 for STVN).
- Company
- DexCom Inc.
- Stevanato Group S.p.A.
- Price
- $71.54+1.52%
- $19.76+1.78%
- Market cap
- $27.61B
- $5.96B
- 1M return
- +2.57%
- +14.75%
- 1Y return
- -20.08%
- -23.40%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- 2021
- News (4w)
- 6
- 1
- Recent ratings
- 25
- 22
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.
Latest DXCM
- Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
- Executive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
Latest STVN
- Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
- Director Balachandran Madhavan was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 5% to 69,458 units (SEC Form 4) to satisfy withholding obligation
- Chief Financial Officer Dal Lago Marco was granted 2,356 units of Ordinary Shares and converted options into 7,997 units of Ordinary Shares, increasing direct ownership by 14% to 85,353 units (SEC Form 4)
- Director Lin Sue-Jean was granted 4,975 units of Ordinary Shares, increasing direct ownership by 249% to 6,975 units (SEC Form 4)
- Director Morel Donald E Jr was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 10% to 37,424 units (SEC Form 4) (tax withholding)
- Director Santel Luciano was granted 4,975 units of Ordinary Shares, increasing direct ownership by 278% to 6,762 units (SEC Form 4)
- Director Magistretti Elisabetta was granted 4,975 units of Ordinary Shares (SEC Form 4)
- Officer Stocchi Mauro was granted 2,101 units of Ordinary Shares and converted options into 6,586 units of Ordinary Shares, increasing direct ownership by 2% to 413,629 units (SEC Form 4)
- Director Flynn Karen was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 153% to 5,757 units (SEC Form 4) (tax withholding)
- Director Federici William J was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 15% to 26,991 units (SEC Form 4) to satisfy withholding obligation